Non-small Cell Lung Cancer

Why trials studying Non-small Cell Lung Cancer stopped, in this sample of ClinicalTrials.gov.

36 stopped trials with a clear reason; 92% ended for non-scientific reasons.

Reason	Trials	Share
slow accrual	17	47%
funding business	15	42%
futility	3	8%
logistics pi	1	3%

Trials

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
NCT05948462 · WITHDRAWN · funding business
“Study withdrawn by pharmaceutical funding partner”
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
NCT06052852 · TERMINATED · funding business
“Sponsor decision”
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
NCT06022757 · TERMINATED · funding business
“Strategic decision by Sponsor.”
A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
NCT05788926 · TERMINATED · funding business
“Sponsor decision not related to safety”
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
NCT05571839 · TERMINATED · funding business
“The trial was terminated for strategic reasons. The decision was not based on any safety concerns.”
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
NCT05374538 · TERMINATED · funding business
“Sponsor decision”
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
NCT05477615 · TERMINATED · slow accrual
“Slow accrual; enrollment was closed after 14 of 28 planned participants.”
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
NCT05194735 · TERMINATED · funding business
“Funding”
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
NCT05234606 · WITHDRAWN · funding business
“Sponsor decision based on strategic re-alignment”
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
NCT04933695 · TERMINATED · futility
“Futility”
Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC
NCT05094544 · WITHDRAWN · slow accrual
“No participants enrolled”
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NCT04875806 · TERMINATED · funding business
“Due to the limited activity in Phase 1, NextCure decided to discontinue development of the anti-B7-H4 antibody monotherapy trial (NC762-01) to move forward with a prioritized B7-H4 ADC program.”
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
NCT04442126 · TERMINATED · funding business
“A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
NCT03968419 · TERMINATED · slow accrual
“Study early terminated due to low enrollment compared to the anticipated figures.”
Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
NCT03166254 · WITHDRAWN · funding business
“Lost funding”
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
NCT03927573 · TERMINATED · funding business
“business decision by sponsor”
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
NCT03829501 · TERMINATED · funding business
“Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
NCT03631199 · TERMINATED · funding business
“Results of primary analysis showed addition of canakinumab to combination treatment did not improve tumor response or overall survival; the decision to stop the trial was not due to safety concerns”
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
NCT03425331 · TERMINATED · slow accrual
“Slow accrual, competing studies, and lack of efficacy”
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
NCT03064854 · TERMINATED · funding business
“Recruitment halted prematurely due to competitive landscape for lung cancer therapies”
Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)
NCT03198117 · TERMINATED · slow accrual
“Difficulty in patient recruitment”
Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
NCT02469701 · TERMINATED · slow accrual
“Lack of accrual”
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
NCT02452424 · TERMINATED · futility
“Terminated early for insufficient evidence of clinical efficacy”
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT02393209 · TERMINATED · futility
“Lack of efficacy in combination.”
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
NCT02274038 · TERMINATED · slow accrual
“Poor Accrual”
Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With Advanced Non-small Cell Lung Cancer
NCT02336061 · TERMINATED · slow accrual
“Sponsor decision due to the low recruitment rate”
Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer
NCT02252796 · TERMINATED · logistics pi
“Investigator left institution”
Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer
NCT02055170 · TERMINATED · slow accrual
“Unable to improve on poor accrual to study.”
Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial
NCT02002052 · TERMINATED · slow accrual
“Insufficient accrual”
Treating NSCLC Minimal Stage IV With Curative Intent
NCT02054819 · TERMINATED · slow accrual
“Didn't meet accrual goal, change in standard of care.”
Multimodal Hypoxia Imaging and Intensity Modulated Radiotherapy for Inoperable Non-small-cell Lung Cancer
NCT01617980 · TERMINATED · slow accrual
“Slow accrual”
Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging
NCT01473693 · TERMINATED · slow accrual
“Lack of Accrual”
Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size
NCT01028612 · TERMINATED · slow accrual
“Slow accrual”
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
NCT00830245 · TERMINATED · slow accrual
“low accrual rate”
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
NCT02157116 · TERMINATED · slow accrual
“Insufficient accrual to meet analysis goals”
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
NCT02127372 · TERMINATED · slow accrual
“The study was closed due to poor accrual”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.